Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor—the importance of gastrointestinal pH and solubility for the in vivo exposure

References

• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res, 19:921–925.
   PubMed Web of Science ®Google Scholar
• Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS et al. (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm, 1:85–96.
   PubMed Web of Science ®Google Scholar
• Hörter D, Dressman JB. (2001). Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev, 46:75–87.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing—oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631–644.
   PubMed Web of Science ®Google Scholar
• Gao L, Zhang D, Chen M. (2008). Drug nanocrystals for the formulation of poorly soluble drugs and its application as a potential drug delivery system. J Nanopart Res, 10:845–862.
   Web of Science ®Google Scholar
• Sigfridsson K, Forssén S, Holländer P, Skantze U, de Verdier J. (2007). A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. Eur J Pharm Biopharm, 67:540–547.
   PubMed Web of Science ®Google Scholar
• Sigfridsson K, Lundqvist AJ, Strimfors M. (2011). Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. Drug Dev Ind Pharm, 37:243–251.
   PubMed Web of Science ®Google Scholar
• Andersson K, Carlsson E. (2005). Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther, 108:294–307.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Reppas C. (2000). In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11 (Suppl 2):S73–S80.
   PubMed Web of Science ®Google Scholar
• Sutton SC. (2004). Companion animal physiology and dosage form performance. Adv Drug Deliv Rev, 56:1383–1398.
   PubMed Web of Science ®Google Scholar
• DeSesso JM, Jacobson CF. (2001). Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem Toxicol, 39:209–228.
   PubMed Web of Science ®Google Scholar
• Nernst W, Brunner E. (1904). Theorie der reaktionsgeschwindigkeit in heterogenen systemen. Z Physik Chemie, 47:52–110.
   Google Scholar
• Liversidge GG, Cundy K. (1995). Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm, 125:91–97.
   Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3–19.
   PubMed Web of Science ®Google Scholar
• Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135–146.
   PubMed Web of Science ®Google Scholar
• Liversidge GG, Conzentino P. (1995). Drug particle reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm, 125:309–313.
   Web of Science ®Google Scholar
• Dressman JB. (1986). Comparison of canine and human gastrointestinal physiology. Pharm Res, 3:123–131.
   PubMed Web of Science ®Google Scholar
• Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman JB et al. (2006). Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res, 23:1373–1381.
   PubMed Web of Science ®Google Scholar
• Jantratid E, Janssen N, Reppas C, Dressman JB. (2008). Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res, 25:1663–1676.
   PubMed Web of Science ®Google Scholar
• Kararli TT. (1989). Gastrointestinal absorption of drugs. Crit Rev Ther Drug Carrier Syst, 6:39–86.
   PubMed Web of Science ®Google Scholar
• Dressman JB, Yamada K. (1991). Animal models for oral drug absorption. In: Welling PG, Tse FLS, Dighe SV. (Eds.), Pharmaceutical Bioequivalence. Marcel Dekker, New York, pp. 235–266.
   Google Scholar
• Watts PJ, Illum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm, 23:893–913.
   Web of Science ®Google Scholar
• Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P et al. (2001). Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci, 12:261–269.
   PubMed Web of Science ®Google Scholar
• Hirasawa N, Ishise S, Miyata H, Danjo K. (2003). An attempt to stabilize nilvadipine solid dispersion by the use of ternary systems. Drug Dev Ind Pharm, 29:997–1004.
   PubMed Web of Science ®Google Scholar
• Morissette SL, Almarsson O, Peterson ML, Remenar JF, Read MJ, Lemmo AV et al. (2004). High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev, 56:275–300.
   PubMed Web of Science ®Google Scholar
• Pudipeddi M, Serajuddin AT. (2005). Trends in solubility of polymorphs. J Pharm Sci, 94:929–939.
   PubMed Web of Science ®Google Scholar
• Serajuddin AT. (2007). Salt formation to improve drug solubility. Adv Drug Deliv Rev, 59:603–616.
   PubMed Web of Science ®Google Scholar
• McNamara DP, Childs SL, Giordano J, Iarriccio A, Cassidy J, Shet MS et al. (2006). Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res, 23:1888–1897.
   PubMed Web of Science ®Google Scholar
• Schultheiss N, Newman A. (2009). Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des, 9:2950–2967.
   PubMed Web of Science ®Google Scholar